conceiv
human
heart
main
sourc
deep
emot
feel
place
consciou
resid
portray
edgar
allan
poe
famou
telltal
heart
short
stori
felt
must
scream
die
louder
louder
louder
louder
dr
john
gibbon
jr
use
first
time
heartlung
respir
keep
patient
aliv
perform
heart
surgeri
dr
norman
shumway
stanford
develop
perfect
first
surgic
techniqu
lead
heart
transplant
surgeri
dr
christian
barnard
first
orthotop
heart
transplant
decemb
dr
shumway
first
heart
transplant
unit
state
januari
heart
transplant
becam
standard
therapeut
option
lifethreaten
congest
failur
start
perform
hundr
next
follow
year
differ
center
heart
transplant
surgeri
face
complic
due
part
reject
infect
howev
develop
select
immunosuppress
therapi
improv
prevent
detect
treatment
infect
allow
heart
transplant
surgeri
increas
rapidli
worldwid
four
thousand
nineti
six
heart
adult
transplant
report
intern
societi
heart
lung
transplant
registri
ishl
landscap
infect
affect
heart
transplant
patient
shape
differ
factor
implement
select
calcineurinbas
immunosuppress
protocol
b
lessen
immunosuppress
induct
regimen
c
institut
antimicrobi
prophylaxi
result
signific
decreas
delay
emerg
major
infect
episod
includ
p
jirovecii
pcp
nocardia
spp
listeria
spp
toxoplasma
gondii
cytomegaloviru
toxoplasmosi
cytomegaloviru
cmv
herp
simplex
viru
cmv
varicella
zoster
viru
vzv
invas
fungal
infect
introduct
novel
diagnost
technolog
facilit
earlier
recognit
treatment
infect
e
expans
criteria
select
donor
recipi
includ
variou
scenario
deal
hbv
hcv
hiv
infect
f
shift
toward
predominantli
gramposit
bacteri
infect
multiresist
bacteria
recent
year
stanford
team
lead
dr
bruce
reitz
perform
lung
transplant
combin
heartlung
transplant
procedur
shortli
thorac
surgeon
optim
singl
doublelung
transplant
procedur
improv
surgic
techniqu
especi
bronchial
anastomosi
evolut
flush
perfus
lung
preserv
decreas
periop
bronchial
complic
substanti
similarli
heart
transplant
improv
immunosuppress
regimen
antimicrobi
prophylaxi
graft
preserv
led
enhanc
surviv
among
lung
transplant
recipi
contrast
cardiac
lung
transplant
face
challeng
infect
uniqu
transplant
organ
mold
infect
anastomot
site
host
versu
graft
diseas
seriou
infect
mycobacterium
abscessu
chlamydia
spp
bronchiol
burkholderia
cepacia
complex
among
infecti
complic
rare
observ
transplant
patient
transplant
thorac
organ
improv
qualiti
life
prevent
death
thousand
individu
worldwid
graft
surviv
life
expect
markedli
improv
patient
due
introduct
optim
immunosuppress
antimicrobi
prophylaxi
diagnost
technolog
allow
earlier
diagnosi
treatment
infect
reject
final
control
infect
like
result
implement
new
approach
assess
net
state
immunosuppress
patient
total
heart
transplant
perform
heart
transplant
recipi
averag
age
year
predominantli
man
signific
histori
smoke
hypertens
cardiomyopathi
follow
coronari
arteri
diseas
lead
caus
transplant
histor
pediatr
adult
transplant
surviv
rate
respect
overal
median
surviv
year
increas
year
surviv
first
year
transplant
although
associ
increas
posttranspl
mortal
infect
transplant
affect
heart
transplant
candid
bronchiti
soft
tissu
infect
commonli
present
despit
major
chang
distribut
caus
death
sinc
infect
remain
predomin
factor
mortal
first
year
transplant
contribut
almost
caus
death
global
incid
infect
heart
transplant
rang
associ
mortal
incid
infect
measur
major
infecti
episod
per
patient
steadili
declin
earli
earli
frequent
type
infect
bacteri
follow
viral
fungal
includ
pneumocysti
jirovecii
protozoa
unfavor
function
outcom
observ
patient
develop
infect
first
year
transplant
mainli
associ
bloodstream
cmv
lung
infect
pulmonari
central
nervou
system
cn
infect
independ
predictor
mortal
among
heart
transplant
recipi
reactiv
latent
parasit
infect
resid
extracardiac
tissu
host
transmit
transplant
heart
import
consider
classic
exampl
reactiv
trypanosoma
cruzi
chaga
diseas
vectorborn
ill
transmit
triatomin
bug
endem
latin
america
ethnic
origin
either
donor
recipi
region
rais
concern
possibl
reactiv
chaga
reactiv
document
case
cohort
brazilian
heart
transplant
recipi
chaga
cardiomyopathi
second
common
indic
transplant
chaga
also
reactiv
transplant
heart
procur
seroposit
donor
transplant
seroneg
recipi
although
substanti
decreas
preval
recent
era
toxoplasmosi
anoth
import
consider
set
similarli
chaga
toxoplasma
predilect
invad
transmit
reactiv
quiescent
cyst
recipi
transplant
heart
adult
receiv
lung
transplant
highest
report
number
procedur
date
driven
mainli
increas
doublelung
transplant
doublelung
transplant
indic
septic
lung
diseas
eg
cystic
fibrosi
around
recipi
age
year
old
frequent
indic
transplant
copd
follow
interstiti
lung
diseas
ild
bronchiectasi
associ
cystic
fibrosi
cf
deficiencyrel
copd
overal
surviv
rate
among
lung
recipi
respect
overal
median
surviv
year
lung
transplant
cmv
seroneg
donor
better
surviv
rate
cmv
seroposit
donor
thirtyday
mortal
led
graft
failur
noncmv
infect
remaind
year
noncmv
infect
lead
caus
death
infect
still
promin
caus
death
follow
first
year
transplant
bronchiol
obliteran
syndrom
bo
chronic
lung
reject
graft
failur
infect
complic
histor
present
among
ten
primari
caus
death
within
first
year
includ
sepsi
pneumonia
fungal
infect
high
lung
alloc
score
la
time
transplant
associ
lower
surviv
higher
rate
infect
among
lung
transplant
recipi
sixtythre
adult
heartlung
transplant
report
ishl
registri
sixtysix
percent
recipi
group
rang
year
old
sixtythre
percent
indic
congenit
heart
diseas
idiopath
pulmonari
arteri
hypertens
heartlung
transplant
cf
higher
europ
center
compar
north
american
compar
lung
transplant
shortterm
surviv
wors
longterm
surviv
better
heartlung
transplant
recipi
surviv
rate
respect
median
surviv
year
year
surviv
first
year
similarli
graft
failur
technic
complic
noncmv
infect
lead
caus
death
first
day
posttranspl
noncmv
infect
top
caus
death
month
within
year
transplant
first
year
boslat
graft
failur
noncmv
infect
predomin
caus
death
among
risk
factor
mortal
lung
transplant
cystic
fibrosi
nosocomi
infect
mechan
ventil
transplant
infect
lung
transplant
recipi
predominantli
bacteri
viral
fungal
mycobacteri
infect
site
pulmonari
risk
factor
infect
vari
type
organ
mechan
ventil
mv
day
immedi
follow
transplant
surgeri
isol
staphylococcu
aureu
sa
airway
cultur
recipi
consid
risk
factor
invas
sa
infect
retrospect
studi
patient
lung
heartlung
transplant
likewis
risk
factor
develop
healthcareassoci
infect
gramneg
organ
aspergillu
legionella
mrsa
methicillinresist
staphylococcu
aureu
includ
prolong
mv
renal
failur
use
atg
antithymocyt
globulin
recurr
reject
episod
addit
defici
repeat
transplant
also
risk
factor
nosocomi
infect
mycobacterium
tuberculosi
transmiss
lung
donor
latent
infect
document
highli
endem
area
colon
mdr
organ
pseudomona
aeruginosa
burkholderia
acinetobact
nontubercul
mycobacteria
ntm
scedosporium
import
cf
predict
develop
challeng
infect
treat
transplant
patient
undergo
comprehens
evalu
potenti
infecti
complic
associ
transplant
detail
medic
histori
includ
previou
vaccin
histori
past
infect
exposur
geograph
occup
anim
etc
travel
foreignborn
statu
among
other
obtain
clinician
shuold
perform
routin
serolog
detect
pathogenspecif
igg
cmv
hsv
ebv
vca
vzv
hepat
b
hbsag
hbsab
hbcab
hiv
hepat
c
syphili
toxoplasma
igg
also
perform
heart
heartlung
transplant
candid
addit
recommend
obtain
ua
urin
cultur
cxr
tuberculin
skin
test
tst
quantiferon
assay
lung
heartlung
transplant
candid
sputum
cultur
bacteri
fungal
afb
studi
center
advoc
screen
patient
colon
mdr
multidrug
resist
bacteria
mrsa
vre
vancomycin
resist
enterococci
may
impact
type
antibacteri
prophylaxi
use
preoper
empir
antibiot
sepsi
develop
immedi
postop
period
potenti
lung
recipi
previou
respiratori
colon
mdr
pseudomona
especi
cf
patient
exclud
transplant
hand
colon
b
cenocepacia
genomovar
iii
cf
present
transplant
rel
contraind
check
endem
fungi
coccidioid
immiti
parasit
trypanosoma
cruzi
strongyloid
stercorali
leishmania
spp
indic
presenc
appropri
risk
factor
histoplasma
capsulatum
reactiv
immunosuppress
therapi
infect
solid
organ
transplant
sot
rare
attribut
transmiss
donor
furthermor
latent
histoplasmosi
present
neg
serolog
treatment
transplant
carri
good
outcom
therefor
role
screen
histoplasmosi
question
signific
type
evalu
may
chang
donor
aliv
deceas
depend
avail
time
collect
sampl
similarli
recipi
donor
undertak
comprehens
assess
includ
complet
histori
assess
risk
factor
exposur
immun
previou
current
infect
donor
screen
hiv
hepat
bc
syphili
tuberculosi
furthermor
recommend
obtain
serolog
cmv
ebv
hsv
vzv
toxoplasma
gondii
endem
area
highrisk
donor
use
nucleic
acid
amplif
test
naat
hbv
hcv
hiv
consid
addit
blood
cultur
document
occult
bacteremia
recommend
lung
transplant
donor
recommend
obtain
respiratori
cultur
bronchoscopi
detect
colon
organ
target
prevent
invas
infect
donor
cultur
media
allograft
acquisit
process
advoc
reduc
risk
mycot
aneurysm
among
kidney
transplant
recipi
may
appli
sot
screen
donor
endem
mycosi
well
establish
hand
heart
transplant
donor
screen
chaga
donor
born
latin
america
final
import
highlight
increas
recognit
emerg
unusu
viral
infect
west
nile
viru
lymphocyt
choriomening
viru
rabi
differ
human
coronavirus
test
organ
done
base
individu
assess
tabl
describ
summar
diagnost
workup
recommend
among
donor
recipi
immun
optim
transplant
sinc
recipi
better
chanc
mount
adequ
immun
respons
advisori
committe
immun
practic
acip
guidelin
immun
solid
organ
transplant
recommend
inactiv
influenza
vaccin
annual
tetanu
diphtheria
acellular
pertussi
tdap
administ
adult
previous
receiv
tdap
unknown
statu
varicella
vaccin
two
dose
patient
without
evid
immun
singl
dose
zoster
vaccin
inactiv
polio
vaccin
hepat
ab
hpv
three
seri
year
age
meningococc
pneumococc
vaccin
administ
remark
import
vaccin
household
member
well
bcg
rabi
vaccin
consid
extenu
exposurerel
indic
see
tabl
educ
patient
famili
member
cornerston
establish
effect
prevent
measur
emphasi
enforc
hand
hygien
food
handl
addit
potenti
sourc
bacteria
fungi
eg
aspergillu
toxoplasmosi
plant
flower
clean
pet
litter
cage
eat
uncook
meat
acquir
new
pet
construct
area
farm
barnyard
activ
smoke
marihuana
avoid
recreat
occup
exposur
unavoid
appropri
gear
glove
must
worn
educ
possibl
commun
exposur
also
import
close
contact
person
fever
rash
potenti
infect
vzv
herp
zoster
influenza
circumv
well
patient
cook
meal
thoroughli
wash
fruit
veget
shun
unpasteur
product
safe
sex
practic
recommend
foreign
travel
plan
seek
evalu
special
travel
clinic
advis
guidelin
manag
surgic
antimicrobi
prophylaxi
list
cefazolin
g
g
patient
weight
kg
everi
h
recommend
regimen
heart
lung
heartlung
transplant
surgeri
clindamycin
mg
everi
h
vancomycin
mgkg
substitut
altern
agent
betalactam
allerg
patient
recommend
adjust
individu
base
local
hospit
surveil
data
previou
knowledg
colon
organ
eg
addit
aztreonam
gentamicin
singlequinolon
dose
howev
widespread
use
quinolon
may
increas
resurg
antimicrobi
resist
antibiot
administ
within
min
surgic
incis
within
min
vancomycin
quinolon
continu
h
heart
transplant
h
longer
day
lung
heartlung
transplant
recipi
recommend
continu
antibacteri
prophylaxi
chest
mediastin
tube
remov
lack
suffici
evid
redos
depend
procedur
durat
associ
blood
loss
recipi
need
treatment
local
infect
present
donor
except
mening
concomit
bacteremia
often
coexist
mening
bacteremia
prudent
treat
recipi
week
indic
antifung
prophylaxi
heart
transplant
recipi
clear
system
review
show
benefit
antifung
therapi
prevent
invas
fungal
infect
transplant
recipi
liver
although
prospect
cohort
heart
transplant
recipi
show
target
echinocandin
median
day
presenc
least
one
risk
factor
invas
aspergillosi
ia
reoper
cytomegaloviru
diseas
posttransplant
hemodialysi
anoth
patient
ia
program
month
procedur
highli
effect
safe
prevent
ia
episod
consensu
exist
univers
antifung
prophylaxi
heart
transplant
recipi
center
adopt
antifung
prophylaxi
includ
inhal
amphotericin
b
oral
itraconazol
iv
target
echinocandin
prophylaxi
lung
lungheart
transplant
recipi
fungal
prophylaxi
consid
especi
pretransplant
respiratori
cultur
either
donor
lung
recipi
airway
show
aspergillu
candida
one
approach
use
inhal
amphotericin
b
mg
extub
intub
patient
respect
daili
day
transplant
weekli
hospit
discharg
patient
known
colon
mold
isol
voriconazol
recommend
month
transplant
although
evid
efficaci
need
confirm
combin
antifung
prophylaxi
therapi
use
center
pneumocysti
jiroveci
prophylaxi
done
trimethoprimsulfamethoxazol
tmpsmx
month
year
center
extend
pjp
prophylaxi
lifelong
tmpsmx
also
confer
protect
toxoplasma
nocardia
listeria
speci
infect
altern
dapson
inhal
pentamidin
atovaquon
use
patient
histori
sulfa
allergi
tmpsmx
recommend
mani
center
lifelong
toxoplasmosi
seroneg
recipi
seroposit
cardiac
donor
toxoplasma
cmv
prevent
recommend
r
patient
two
common
strategi
cmv
prevent
antivir
prophylaxi
preemptiv
therapi
approach
possess
similar
success
rate
advantag
disadvantag
guidelin
recommend
valganciclovir
intraven
ganciclovir
prefer
antivir
oral
ganciclovir
option
heart
transplant
patient
although
possess
low
oral
bioavail
therefor
theoret
risk
increas
resist
often
cmv
immun
globulin
use
adjunct
agent
heart
recipi
prophylaxi
recommend
month
month
r
lung
heartlung
recipi
durat
prophylaxi
month
month
r
recipi
respect
patient
otherwis
receiv
cmv
activ
agent
antivir
prophylaxi
herp
virus
hsv
vzv
consid
use
oral
oral
liposom
formul
cidofovir
hematopoieticcel
transplant
reduc
cmvrelat
event
may
potenti
role
prevent
cmv
transplant
set
refer
tabl
list
prophylaxi
recommend
period
character
commonli
nosocomi
bacteri
infect
thu
bacteri
organ
present
often
mdr
eg
vre
mrsa
heart
transplant
recipi
skin
soft
tissu
infect
ssti
surgic
site
infect
mediastin
concern
period
likewis
lung
lungheart
transplant
recipi
may
develop
infect
relat
previou
respiratori
colon
pseudomona
aspergillu
signific
infect
includ
aspir
pneumon
healthcar
ventilatorassoci
pneumonia
catheterrel
bloodstream
infect
crbsi
nosocomi
uti
clostridium
difficil
coliti
donorderiv
infect
period
present
includ
hsv
lymphocyt
choriomening
viru
lcmv
rhabdoviru
rabi
west
nile
viru
wnv
hiv
toxoplasma
gondii
trypanosoma
cruzi
also
seriou
donorderiv
infect
heart
transplant
recipi
develop
within
first
month
posttransplant
period
reactiv
latent
infect
usual
occur
henc
bacteri
infect
caus
nocardia
asteroid
listeria
monocytogen
mycobacteria
tuberculosi
typic
occur
addit
fungal
infect
aspergillu
spp
cryptococcu
neoforman
p
jiroveci
parasit
toxoplasma
gondii
leishmania
spp
strongyloid
trypanosoma
cruzi
also
seen
viral
infect
present
period
includ
herpesvirus
hsv
vzv
cmv
ebv
adenoviru
develop
infect
month
predominantli
communityacquir
pneumonia
urinari
tract
infect
diseas
includ
aspergillu
mucor
speci
nocardia
rhodococcu
late
viral
infect
includ
cmv
hepat
b
c
jc
polyomaviru
infect
posttranspl
lymphoprolif
disord
ptld
hsv
enceph
viral
communityacquir
infect
eg
coronaviru
west
nile
viru
influenza
import
recogn
transplant
recipi
patient
popul
increas
suscept
infect
low
threshold
perform
diagnost
workup
presenc
concern
sign
symptom
infect
monitor
also
done
structur
way
preemptiv
therapi
cmv
place
oppos
univers
prophylaxi
protocol
vari
transplant
center
usual
impli
weekli
cmv
pcr
ag
monitor
likewis
monitor
cellmedi
immun
cmi
use
quantiferoncmv
assay
may
use
predict
lateonset
cmv
diseas
cmv
prophylaxi
stop
cmi
also
monitor
ebv
use
enzymelink
immunospot
assay
immunoglobulin
g
igg
level
nk
cell
count
propos
attempt
identifi
risk
infect
heart
transplant
recipi
within
first
year
signific
drugdrug
interact
exist
among
antimicrobi
immunosuppress
agent
patient
medic
list
review
care
strong
induc
nafcillin
reduc
tacrolimu
serum
concentr
contrast
azol
fluconazol
result
increas
level
tacrolimu
cyclosporin
voriconazol
dose
tacrolimu
need
reduc
twothird
cyclosporin
dose
rifamycin
opposit
drugdrug
interact
decreas
concentr
prednison
cyclosporin
tacrolimu
sirolimu
mycophenol
mofetil
mmf
likewis
tacrolimu
administr
along
quinolon
may
caus
qt
prolong
heart
transplant
patient
bacteri
infect
similar
clinic
manifest
commonli
observ
patient
popul
howev
clinic
sign
may
subtl
absent
eg
afebril
frequent
type
infect
set
reach
infect
common
pulmonari
infect
follow
bacteremia
mediastin
skin
infect
staphylococcu
caus
ssti
ventilatorassoci
pneumonia
mediastin
crbsi
form
bacteremia
osteomyel
contrast
coagulaseneg
staphylococcu
commonli
associ
crbsi
among
gramneg
bacteria
pseudomona
aeruginosa
common
usual
pulmonari
origin
escherichia
coli
primari
causal
organ
uti
extendedspectrum
esbl
produc
klebsiella
pneumonia
escherichia
coli
klebsiella
oxytoca
citrobact
freundii
also
found
heart
transplant
recipi
nocardia
speci
well
recogn
opportunist
pathogen
set
although
rel
rare
heart
transplant
recipi
frequenc
nocardia
second
frequenc
heart
transplant
lung
transplant
recipi
pertinentindepend
risk
factor
associ
develop
infect
sot
includ
highdos
steroid
histori
cmv
diseas
high
level
calcineurin
inhibitor
almost
univers
prophylaxi
tmpsmx
nocardia
infect
less
common
often
present
late
usual
year
posttranspl
occur
affect
lung
predominantli
port
entri
dissemin
infect
cn
invas
also
caus
skin
nodul
abscess
listeria
monocytogen
also
seen
heart
transplant
recipi
count
signific
proport
bacteri
mening
case
set
addit
myocard
myocardi
abscess
organ
also
document
mycobacterium
tuberculosi
nontubercul
mycobacteria
ntm
although
document
occur
heart
transplant
rare
unit
state
howev
import
recogn
develop
tuberculosi
tb
preval
endem
region
often
present
extrapulmonari
involv
legionellosi
rhodococcu
equi
mainli
pulmonari
manifest
pneumonia
pulmonari
infiltr
cavit
anoth
signific
infect
among
heart
transplant
recipi
fungal
infect
exclud
pcp
repres
around
infect
invas
mold
infect
imi
signific
contribut
morbid
mortal
among
heart
transplant
recipi
incid
popul
reach
per
personyear
associ
mortal
approxim
aspergillu
repres
imi
median
time
onset
day
although
late
present
day
recent
recogn
associ
receipt
sirolimu
conjunct
tacrolimu
refractori
reject
cardiac
allograft
vasculopathi
common
clinic
present
aspergillosi
includ
fever
cough
singl
multipl
pulmonari
nodul
extrapulmonari
manifest
includ
spondylodisc
infect
endocard
mediastin
endophthalm
brain
cutan
abscess
dissemin
tend
affect
cn
good
proport
case
mucormycosi
second
frequent
mold
affect
heart
transplant
recipi
mucor
along
nonaspergillu
mold
eg
scedosporium
ochroconi
gallopava
associ
dissemin
infect
cn
involv
poorer
outcom
pneumocysti
jiroveci
pcp
mark
reduct
incid
introduct
univers
still
signific
pathogen
case
may
occur
late
heart
transplant
cryptococcosi
although
infrequ
among
sot
patient
higher
incid
heart
transplant
recipi
usual
manifest
present
late
affect
lung
cn
predominantli
histoplasmosi
coccidioidomycosi
occur
typic
first
year
transplant
antigenuria
sensit
diagnost
test
sot
histoplasmosi
final
candida
infect
import
caus
morbid
mortal
well
rate
colon
higher
gener
popul
candida
commonli
caus
oral
mucosa
infect
although
declin
invas
infect
time
occur
typic
form
bloodstream
infect
secondari
catheterrel
infect
tracheobronch
dissemin
diseas
addit
confin
endorgan
injuri
endophthalm
esophag
also
seen
cmv
infect
critic
import
among
sot
heart
transplant
recipi
cmv
inconsist
associ
cardiac
allograft
vasculopathi
furthermor
cmv
lead
upregul
proinflammatori
cytokin
increas
procoagul
respons
left
ventricular
dysfunct
allograft
reject
increas
opportunist
infect
greatest
risk
develop
cmv
diseas
cmvneg
recipi
cmvposit
organ
follow
dr
clinic
report
estim
rate
infect
heart
transplant
rang
diseas
present
around
patient
clinic
manifest
uniqu
heart
transplant
recipi
includ
cmv
syndrom
fever
myalgia
arthralgia
malais
leukopenia
thrombocytopenia
cmvassoci
endorgan
injuri
set
includ
frequent
pneumon
gastrointestin
diseas
manifest
compris
myelosuppress
hepat
pancreat
contrast
high
frequenc
observ
aid
patient
chorioretin
heart
transplant
patient
rel
rare
guidelin
cmv
diagnosi
manag
discuss
detail
chap
also
publish
elsewher
herp
virus
import
consider
well
ebvassoci
tcell
ptld
frequent
heart
transplant
recipi
sot
patient
ptld
signific
contributor
morbid
mortal
pediatr
heart
transplant
popul
human
tlymphotrop
viru
type
human
herp
viru
hhv
might
play
role
ebv
tcell
ptld
well
herp
virus
manifest
host
mucocutan
lesion
hsv
herp
zoster
vzv
infecti
mononucleosi
case
ebv
kaposi
sarcoma
enceph
hepat
coliti
pneumon
gastrointestin
diseas
also
attribut
dissemin
certain
herp
virus
herp
virus
present
dissemin
skin
lesion
without
vesicl
format
fever
unknown
origin
adenoviru
associ
reject
ventricular
dysfunct
coronari
vasculopathi
need
retransplant
current
standard
treatment
adenoviru
cidofovir
outcom
optim
chronic
hepat
without
identifi
caus
prompt
test
hepat
e
viru
hev
chronic
hev
infect
lead
rapid
develop
fibrosi
hev
test
done
rna
pcr
due
delay
antibodi
respons
recommend
decreas
immunosuppress
ribavirin
therapi
month
less
common
manifest
consid
correct
epidemiolog
risk
factor
includ
myelopathi
rabi
lymphocyt
choriomening
viru
subacut
measl
enceph
mump
associ
parot
orchiti
vestibular
neuriti
allograft
involv
dengu
viru
orf
viru
human
coronaviru
influenza
cardiac
transplant
one
predictor
develop
toxoplasmosi
associ
risk
factor
includ
neg
serum
statu
transplant
diagnosi
cytomegaloviru
cmv
infect
highdos
prednison
toxoplasmosi
transmit
donor
heart
especi
first
month
reactiv
recipi
month
infect
develop
first
month
posttranspl
predominantli
primari
infect
infect
patient
dissemin
infect
carri
estim
mortal
toxoplasmosi
manifest
otherwis
myocard
enceph
pneumon
chorioretin
diagnosi
requir
identif
tissu
cyst
surround
abnorm
inflammatori
respons
detect
toxoplasma
dna
bodi
fluid
pcr
posit
toxoplasmaspecif
immunohistochemistri
affect
organ
posttranspl
serolog
test
help
diagnosi
may
mislead
sinc
result
may
chang
regardless
presenc
toxoplasmosi
prefer
treatment
regimen
combin
pyrimethamin
sulfadiazin
advanc
chagas
cardiomyopathi
primari
indic
heart
transplant
center
trypanosoma
cruzi
causal
organ
chaga
diseas
transmit
time
infect
heart
donor
addit
chaga
diseas
reactiv
donor
immunosuppress
place
r
reactiv
rate
rang
recipi
chronic
chagas
cardiomyopathi
undergo
heart
transplant
addit
risk
factor
reactiv
includ
reject
episod
neoplasm
use
mmf
mean
onset
symptom
approxim
day
manifest
chaga
present
nonspecif
symptom
fever
malais
anorexia
hepatosplenomegali
lymphadenopathi
myocard
pericard
enceph
also
seen
reactiv
mimic
reject
exhibit
congest
heart
failur
av
block
skin
manifest
nodul
pannicul
increas
eosinophil
count
anemia
indirect
indic
reactiv
diagnosi
made
visual
circul
trypomastigot
peripher
blood
addit
blood
tissu
pcr
use
tissu
amastigot
seen
biopsi
h
e
prepar
fig
final
serolog
crucial
aspect
diagnosi
especi
seroconvers
document
asymptomat
individu
diagnosi
chaga
establish
donor
monitor
institut
weekli
blood
cruzi
pcr
microscopi
prefer
antitrypanosom
therapi
consist
benznidazol
nifurtimox
altern
treatment
option
posaconazol
antiparasit
activ
carri
high
failur
rate
gi
diseas
isospora
cystoisospora
belli
cryptosporidium
cyclospora
microsporidia
report
affect
sot
recipi
microsporidiosi
manifest
dissemin
diseas
fever
keratoconjunct
cn
involv
cholang
cough
thoracicabdomin
pain
rare
parasit
infect
affect
heart
transplant
includ
leishmaniasi
strongyloidiasi
freeliv
amoeba
rate
surgic
site
infect
ssi
wound
patient
receiv
antimicrobi
prophylaxi
rang
follow
heart
transplant
procedur
heart
transplant
independ
risk
factor
ssi
risk
factor
includ
age
prophylaxi
ciprofloxacin
alon
posit
wire
cultur
femal
gender
previou
left
ventricular
assist
devic
vad
placement
bmi
previou
cardiac
procedur
inotrop
support
hemodynam
instabl
similarli
host
staphylococcu
speci
predomin
organ
caus
ssti
mrsa
reach
case
gramposit
organ
vre
e
faecali
coagulaseneg
staphylococci
enterococcu
speci
etiolog
agent
candida
select
gram
neg
enterobacteriacea
p
aeruginosa
stenotrophomona
maltophilia
caus
ssi
well
sternal
osteomyel
often
complic
deep
ssi
addit
sternal
wound
infect
ntm
fungi
aspergillu
scedosporium
document
herp
zoster
also
import
consider
sourc
morbid
herp
zoster
hz
found
complic
patient
median
time
present
rang
year
close
half
may
develop
postherpet
neuralgia
multidermatom
involv
zoster
ophthalmicu
meningoenceph
also
describ
exposur
mmf
independ
risk
factor
convers
cmv
prophylaxi
reduc
risk
hz
bloodstream
infect
bsi
risk
factor
mortal
among
heart
transplant
recipi
likewis
sot
recipi
statu
independ
risk
factor
develop
bacteremia
heart
transplant
recipi
rate
bsi
rang
median
onset
day
sourc
order
frequenc
lower
respiratori
tract
urinari
tract
crbsi
gramneg
bacteria
commonli
isol
order
appear
e
coli
p
aeruginosa
k
pneumonia
common
gramposit
bacteria
aureu
epidermidi
e
faecali
l
monocytogen
directli
attribut
mortal
among
identifi
independ
risk
factor
develop
bsi
hemodialysi
prolong
intens
care
unit
stay
viral
infect
infect
endocard
ie
seen
frequent
among
heart
transplant
recipi
gener
popul
ie
occur
commonli
involv
mitral
tricuspid
valv
staphylococcu
aureu
aspergillu
main
etiolog
organ
main
predispos
factor
set
believ
frequent
use
vascular
indwel
cathet
frequenc
endomyocardi
biopsi
staphylococcu
aureu
bacteremia
heart
transplant
recipi
rang
sourc
sa
bacteremia
sot
crbsi
pneumonia
wound
endocard
intraabdomin
infect
bone
joint
cardiac
devic
uti
ssti
immedi
follow
heart
transplant
month
patient
suscept
develop
pneumonia
healthcar
ventil
associ
therefor
caus
nosocomi
organ
mrsa
pseudomona
aeruginosa
gram
neg
includ
acinetobact
esblenterobacteriacea
pneumonia
one
major
contributor
mortal
earli
postop
period
pneumoniarel
mortal
approach
month
interstiti
pneumonia
pneumon
develop
differenti
includ
herpesvirus
hsv
cmv
vzv
respiratori
syncyti
viru
rsv
toxoplasma
gondii
pneumocysti
jiroveci
pulmonari
nodul
without
cavit
caus
fungi
coccidioidomycosi
aspergillosi
mucormycosi
cryptococcosi
bacteri
includ
actinomycosi
tuberculosi
atyp
mycobacteri
infect
nocardia
rhodococcu
equi
gramneg
bacilli
noninfecti
caus
like
pulmonari
infarct
lymphoprolif
disord
pulmonari
nodul
seen
patient
median
detect
time
day
associ
symptom
fever
cough
frequent
etiolog
aspergillu
follow
nocardia
rhodococcu
cmv
exceedingli
rare
caus
pulmonari
nodul
diagnost
approach
higher
yield
transthorac
fine
needl
aspir
follow
bronchoalveolar
lavag
transtrach
aspir
communityacquir
pneumonia
caus
streptococcu
pneumonia
legionella
spp
mycoplasma
influenza
anoth
sourc
morbid
mediastin
common
complic
set
patient
receiv
antimicrobi
prophylaxi
mediastin
develop
patient
ct
scan
usual
necessari
determin
extens
infect
mrsa
staphylococcu
epidermidi
gramneg
bacteria
aspergillu
fumigatu
frequent
found
causal
organ
antimicrobi
therapi
accompani
aggress
surgic
debrid
distinct
abdominalpelv
complic
among
heart
transplant
recipi
clostridium
difficil
common
hospitalrel
caus
diarrhea
associ
use
antimicrobi
etiolog
diarrhea
secondari
acut
gastroenter
present
protract
way
set
listeria
infect
present
febril
gastroenter
ill
well
nontyphoid
salmonella
infect
describ
complic
earli
postop
period
center
taiwan
acut
cholecyst
affect
heart
transplant
recipi
advoc
low
threshold
use
ultrasound
screen
method
acut
pancreat
abscess
format
also
describ
point
hepat
e
present
persist
abnorm
liver
test
although
less
frequent
kidney
transplant
recipi
urinari
tract
infect
import
caus
morbid
uti
predispos
foley
cathet
organ
commonli
involv
gramneg
bacteria
enterococcu
candida
polyomaviru
nephropathi
bk
viru
describ
heart
transplant
recipi
might
contributor
chronic
kidney
diseas
need
urgent
transplant
multipl
transfus
independ
associ
infecti
neurolog
complic
overal
mortal
reach
donorderiv
meningoencephalitid
affect
heart
transplant
recipi
usual
manifest
within
first
day
infect
includ
west
nile
viru
arenavirus
eg
lcmv
rabi
wnv
manifest
axonopathi
cerebrospin
fluid
csf
pleocytosi
addit
mening
enceph
ataxia
myeliti
optic
neuriti
polyradicul
seizur
also
observ
wnv
also
acquir
recipi
commun
blood
transfus
present
later
time
infecti
form
mening
enceph
present
month
includ
listeriosi
streptococcu
pneumonia
trypanosoma
cruzi
toxoplasma
dissemin
herp
viru
infect
cmv
vzv
hsv
ebv
absenc
appropri
primari
prophylaxi
monitor
increas
risk
aspergillu
caus
major
brain
abscess
addit
toxoplasma
tuberculosi
listeria
spp
cryptococcu
neoforman
scedosporium
spp
nocardia
also
caus
agent
concomit
pulmonari
involv
common
particularli
whose
portal
entri
respiratori
tract
progress
multifoc
leukoencephalopathi
pml
demyelin
diseas
caus
reactiv
jc
viru
usual
median
onset
month
carri
mark
high
case
fatal
rate
median
surviv
month
sot
use
rituximab
antireject
treatment
seem
confer
increas
risk
pml
myelopathi
ham
describ
well
sot
bacteri
infect
common
type
infect
among
lung
lungheart
transplant
recipi
anatom
site
frequent
affect
respiratori
tract
usual
manifest
pneumonia
sinus
tracheobronch
previou
colon
healthcar
associ
procedur
relat
primari
sourc
patient
cystic
fibrosi
cf
knowledg
previou
colon
result
may
provid
diagnost
therapeut
advantag
pseudomona
aeruginosa
predomin
colon
pathogen
cf
howev
acinetobact
baumannii
burkholderia
speci
stenotrophomona
maltophilia
achromobact
xylosoxidan
ntm
pandorea
ralstonia
also
observ
furthermor
pathogen
known
caus
nosocomi
pneumonia
month
includ
staphylococcu
aureu
pseudomona
aeruginosa
gram
neg
klebsiella
pneumonia
enterobact
cloaca
serratia
marcescen
escherichia
coli
acinetobact
speci
anaerob
gramposit
bacteria
common
sourc
infect
make
common
site
affect
respiratori
tract
follow
bacteremia
skin
wound
cathet
relat
pathogen
frequent
identifi
staphylococcu
speci
enterococcu
speci
streptococcu
speci
pneumococcu
eubacterium
lentum
staphylococcu
aureu
infect
develop
lung
recipi
sa
commonli
caus
pneumonia
follow
tracheobronch
bacteremia
intrathorac
infect
ssti
streptococcu
pneumonia
commun
acquir
present
pneumonia
usual
month
posttranspl
pseudomona
aeruginosa
high
rate
colon
diseas
signific
bacteri
infect
may
present
month
mycobacterium
tuberculosi
ntm
nocardia
rhodococcu
legionella
isol
ntm
lung
transplant
recipi
without
evid
diseas
associ
increas
mortal
nocardiosi
occur
lung
transplant
recipi
median
time
onset
rang
month
nocardia
asteroid
n
farcinica
n
nova
n
brasiliensi
report
n
farcinica
appear
carri
wors
outcom
infect
present
breakthrough
presenc
trimethoprimsulfamethoxazol
p
jiroveci
prophylaxi
although
isol
may
remain
suscept
mortal
report
rang
nativ
lung
frequent
affect
singlelung
transplant
recipi
nodul
preval
radiograph
find
extrapulmonari
involv
affect
skin
brain
seen
hypogammaglobulinemia
neutropenia
seem
confer
addit
risk
factor
nocardiosi
set
fungal
infect
frequent
complic
lung
lungheart
transplant
present
carri
overal
mortal
close
aspergillu
candida
frequent
caus
agent
import
fungi
includ
cryptococcu
spp
mucormycosi
endem
fungi
histoplasma
coccidioid
blastomyc
spp
scedosporium
spp
fusarium
spp
dematiac
mold
candida
infect
promin
month
transplant
one
common
caus
bsi
set
although
colon
upper
airway
gastrointestin
tract
common
candida
addit
caus
mucocutan
diseas
tracheobronch
anastomosi
site
infect
crbsi
dissemin
diseas
aspergillu
spp
lead
caus
invas
fungal
infect
attack
rate
infect
almost
ten
time
compar
sot
patient
estim
incid
among
lung
transplant
recipi
fumigatu
common
speci
terreu
flavu
niger
describ
well
main
predispos
risk
factor
set
intens
immunosuppress
previou
colon
aspergillu
spp
airway
ischemia
bo
singlelung
transplant
possess
greatest
risk
develop
invas
aspergillu
infect
carri
higher
mortal
doublelung
heartlung
transplant
recipi
singlelung
recipi
usual
older
like
copd
indic
transplant
aspergillu
infect
present
tracheobronch
pneumonia
dissemin
diseas
extrapulmonari
involv
includ
sinus
cn
orbit
infect
vertebr
osteomyel
aid
diagnosi
includ
surveil
bronchoscopi
bronchoalveolar
lavag
stain
cultur
biopsi
chest
ct
serumb
galactomannan
betadglucan
pcr
presenc
pulmonari
nodular
lesion
invas
infect
carri
better
outcom
voriconazol
treatment
choic
import
note
immun
reconstitut
inflammatori
syndrom
iri
develop
median
day
treat
lung
transplant
recipi
aspergillu
tracheobronch
nebul
amphotericin
b
debrid
bronchial
anastomosi
import
adjuv
measur
system
antifung
therapi
pneumocysti
jirovecii
pneumonia
manifest
month
incid
reduc
dramat
univers
tmpsmx
prophylaxi
cryptococcosi
rate
lung
transplant
recipi
present
pulmonari
involv
dissemin
mening
occur
furthermor
cryptococcu
skin
manifest
like
cellul
cryptococcusassoci
iri
document
viral
infect
common
caus
morbid
among
lung
transplant
recipi
common
virus
cmv
among
herp
virus
communityacquir
respiratori
virus
sot
recipi
higher
risk
develop
cmv
infect
among
follow
dr
last
scenario
carri
less
risk
lung
transplant
recipi
possess
higher
risk
cmv
sot
estim
incid
lung
consid
primari
reservoir
cmv
latenc
abund
lymphocyt
tissu
surround
transplant
organ
addit
use
antilymphocyt
antibodi
treat
reject
immunosuppress
herpesvirus
infect
addit
risk
factor
cmv
diseas
interferon
ifn
polymorph
increas
ifn
level
may
predisposit
cmv
diseas
cmv
significantli
associ
bo
reduc
surviv
first
year
posttranspl
cmv
diseas
commonli
manifest
pneumon
viral
syndrom
less
frequent
gastrointestin
diseas
among
lung
transplant
recipi
ganciclovirresist
cmv
carri
increas
morbid
mortal
infect
communityacquir
respiratori
virus
rang
infect
associ
increas
risk
develop
pneumonia
graft
dysfunct
manifest
lung
function
loss
bo
high
calcineurin
inhibitor
blood
level
increas
mortal
virus
includ
influenza
parainfluenza
respiratori
syncyti
viru
rsv
coronavirus
human
rhinoviru
adenoviru
human
metapneumovirus
bocavirus
hospit
rate
higher
influenza
parainfluenza
respect
symptom
usual
nonspecif
diagnosi
often
requir
detect
viral
nucleoprotein
antigen
nasopharyng
swab
bronchoalveolar
lavag
bal
enzym
immunoassay
fluoresc
antibodi
amplif
nucleic
acid
pcr
ribavirin
may
possess
activ
paramyxovirus
rsv
metapneumoviru
parainfluenza
ribavirin
administ
inhal
oral
intraven
oseltamivir
zanamivir
treatment
choic
influenza
b
adamantan
amantadin
rimantadin
activ
influenza
b
mark
increas
resist
among
influenza
strain
similarli
sot
recipi
dna
virus
like
noncmv
herpesvirus
vzv
ebv
sourc
signific
morbid
includ
limit
cmvneg
viral
syndrom
rash
pneumon
hepat
enceph
lastli
polyomaviru
bk
viru
bkv
jc
viru
jcv
simian
viru
frequent
encount
lung
transplant
recipi
unclear
caus
worsen
renal
function
surviv
ptld
also
wellrecogn
complic
trend
toward
late
ptld
present
year
document
b
symptom
predomin
well
extragraft
involv
immunosuppress
state
certain
parasit
infect
complic
lung
heartlung
transplant
recipi
critic
elicit
detail
histori
geograph
risk
factor
determin
risk
acquisit
potenti
etiolog
agent
toxoplasmosi
result
primari
infect
reactiv
previou
latent
infect
toxoplasmosi
develop
patient
neg
epidemiolog
histori
cat
ownership
consumpt
undercook
meat
patient
primari
toxoplasmosi
nonspecif
symptom
fever
lymphadenopathi
organ
injuri
may
present
reactiv
caus
enceph
without
spaceoccupi
brain
lesion
seizur
chorioretin
fever
unknown
origin
pneumon
myocard
rash
although
case
lung
fluke
paragonimu
westermani
report
lung
transplant
potenti
threat
endem
area
organ
endem
parasit
target
lung
immunosuppress
state
includ
echinococcu
schistosoma
strongyloid
stercorali
strongyloidiasi
present
hyperinfect
syndrom
leishmania
although
infrequ
seen
report
among
lung
lungheart
recipi
freeliv
amoeba
affect
popul
well
amoeb
granulomat
dermat
dissemin
infect
present
ulcer
skin
lesion
respiratori
failur
seizur
describ
lung
transplant
recipi
final
alimentari
protozoa
includ
cryptosporidium
present
diarrhea
may
elev
tacrolimu
level
microsporidia
present
unusu
manifest
like
myositi
granulomat
interstiti
nephriti
affect
lung
transplant
recipi
overal
rate
ssi
signific
proport
infect
organ
space
occupi
deep
incision
superfici
independ
risk
factor
develop
ssi
diabet
femal
donor
prolong
ischem
time
number
red
blood
cell
transfus
periop
period
ssi
associ
mortal
within
first
year
transplant
common
organ
found
caus
ssi
mediastin
p
aeruginosa
candida
speci
aureu
includ
mrsa
enterococcu
coagulaseneg
staphylococci
burkholderia
cepacia
e
coli
proteu
mirabili
serratia
marcescen
acinetobact
baumannii
enterobact
cloaca
klebsiella
speci
correl
patient
ssi
caus
organ
previou
pathogen
colon
recipi
nativ
lung
time
transplant
median
onset
day
lung
transplant
although
rare
ntm
caus
ssi
infect
among
lung
transplant
recipi
frequent
encount
mycobacterium
avium
complex
follow
mycobacterium
abscessu
mycobacterium
gordona
ntm
ssi
infect
complic
progress
dissemin
diseas
requir
lifelong
suppress
therapi
organ
mycoplasma
homini
lactobacillu
spp
also
describ
deep
infect
affect
patient
sternal
osteomyel
reach
deep
infect
caus
organ
sternal
osteomyel
includ
pseudomona
aeruginosa
serratia
marcescen
scedosporium
nonstern
osteomyel
affect
calcaneu
bone
complic
dissemin
infect
aspergillu
fumigatu
bloodstream
infect
bsi
occur
estim
rate
among
lung
transplant
recipi
major
proport
bsi
occur
earli
posttranspl
period
bsi
infect
significantli
associ
wors
surviv
common
organ
encount
staphylococcu
aureu
pseudomona
aeruginosa
candida
pseudomona
aeruginosa
present
transplant
hospit
period
commonli
affect
cf
follow
frequenc
burkholderia
cepacia
candida
albican
convers
staphylococcu
aureu
predomin
organ
transplant
discharg
estim
bsi
sourc
pulmonari
follow
frequenc
crbsi
gastrointestin
infect
periton
uti
pulmonari
sourc
bacteremia
sot
often
develop
septic
shock
although
unusu
case
aspergillu
fumigatu
endocard
describ
follow
lung
transplant
often
patient
cf
underli
lung
diseas
median
month
present
complic
carri
high
mortal
often
requir
combin
antifung
therapi
valvular
replac
surgeri
infecti
complic
relat
chest
caviti
includ
mediastin
cardiac
pericard
myocard
lung
parenchyma
infect
nodular
infiltr
cavit
pneumonia
bronchial
anastomosi
infect
pleural
space
infect
bronchopleur
fistula
empyema
empyema
follow
mediastin
pericard
addit
surgic
wound
infect
sternal
osteomyel
frequent
deep
ssi
complic
affect
chest
caviti
empyema
present
around
case
occur
first
month
transplant
median
day
carri
estim
mortal
common
organ
found
staphylococcu
spp
e
coli
enterobact
spp
klebsiella
spp
mycoplasma
homini
vre
candida
furthermor
mycobacterium
abscessu
isol
rare
caus
agent
empyema
well
degre
immunosuppress
reduc
renal
function
previou
sternotomi
reexplor
due
bleed
list
potenti
risk
factor
mediastin
increas
preval
mediastin
caus
gram
neg
fungi
among
lung
transplant
recipi
caus
organ
mediastin
similar
ssi
list
infecti
pericard
present
patient
isol
organ
includ
mssa
mycoplasma
homini
scedosporium
prolifican
due
high
fatal
rate
fungal
bronchial
anastomot
infect
critic
recogn
pneumonia
believ
affect
around
lung
recipi
heartlung
recipi
nosocomi
organ
caus
earli
pneumonia
posttranspl
set
donor
lung
seem
primari
sourc
pneumon
infect
although
recipi
upper
airway
sinus
also
potenti
sourc
preoper
colon
gramneg
rod
colon
infect
donor
bronchu
perfus
recogn
risk
factor
pneumonia
likewis
pretransplant
colon
microorgan
suppur
lung
diseas
associ
pneumonia
develop
posttranspl
common
causal
organ
pseudomona
aeruginosa
staphylococcu
aureu
aspergillu
spp
pathogen
includ
bacteria
b
cepacia
enterobact
speci
maltophilia
klebsiella
speci
epidermidi
e
coli
fungi
fusarium
spp
cryptococcu
neoforman
paracoccidioid
brasiliensi
month
pneumonia
present
local
infiltr
diffus
interstiti
infiltr
nodul
without
cavit
type
present
may
aid
possibl
caus
microorgan
list
potenti
pathogen
extens
includ
addit
alreadi
mention
nocardia
chlamydia
pneumonia
legionella
tb
ntm
pneumocysti
jirovecii
rhodococcu
herpesvirus
cmv
hsv
vzv
respiratori
virus
endem
fungi
eg
histoplasmosi
mucormycosi
scedosporium
spp
similarli
sot
common
infecti
complic
affect
gastrointestin
genitourinari
tract
includ
clostridium
difficil
coliti
uti
intraabdomin
complic
carri
overal
increas
mortal
frequent
gi
symptom
present
posttranspl
diarrhea
affect
almost
lung
transplant
recipi
abdomin
pain
abdomin
pain
prompt
investig
potenti
intraabdomin
caus
pediatr
popul
possibl
ptld
investig
sinc
carri
high
mortal
describ
infecti
intraabdomin
complic
includ
digest
perfor
seen
retroperiton
abscess
cholecyst
perian
abscess
esophag
pancreat
pancreat
abscess
hepat
diverticul
append
cmv
coliti
megacolon
colon
ruptur
develop
countri
persist
abnorm
liver
enzym
prompt
test
hev
hev
rna
use
screen
oral
ribavirin
seem
safe
effect
set
cn
symptom
develop
month
follow
lung
heartlung
transplant
trigger
concern
donorderiv
viral
infect
lcmv
often
accompani
csf
normal
low
glucos
mark
elev
protein
mild
pleocytosi
although
unclear
benefit
ribavirin
use
donortransmit
rabi
uncommon
neurolog
devast
complic
occur
within
first
day
transplant
lung
transplant
describ
potenti
causal
mechan
organ
known
caus
mening
lung
transplant
recipi
cryptococcu
tuberculosi
wnv
herpesvirus
diagnosi
wnv
set
requir
nuclear
acid
amplif
due
unreli
serolog
test
scedosporium
apiospermum
infect
often
caus
dissemin
includ
cn
abscess
addit
pulmonari
involv
among
lung
transplant
recipi
import
differenti
mold
sinc
amphotericin
b
ineffect
scedosporium
spp
sever
case
refractori
diseas
without
appropri
surgic
debrid
addit
terbinafin
voriconazol
may
prove
use
recogn
organ
caus
occupi
brain
lesion
fusarium
nocardia
aspergillu
toxoplasmosi
cryptococcu
neoforman
listeria
cladophialophora
bantiana
pml
late
manifest
associ
intensifi
immunosuppress
rituximab
cidofovir
follow
mirtazapin
consid
form
therapi
pml
infect
heart
lung
heartlung
transplant
recipi
complex
dynam
evolv
process
mani
factor
demograph
time
type
transplant
anatomi
microbiolog
among
other
interplay
develop
fatal
complic
pertin
recognit
treatment
infect
improv
transplant
outcom
